As a low quality, weak recommendation, it is part of the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults, that patient with a GCS of 14-15 and anticoagulation therapy and a normal CT should be admitted for observation for at least 24 hours. No data are available on the adverse events related to the observational 24-hour admission. The aim was to evaluate the risk of post-CT hemorrhage as well as the risk of complications to an admission (e.g. deleria, thrombosis due to pause of antithrombotic medications.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Minimal (defined according to the Head Injury Severity Score (HISS (Stein and Spettell 1995)) as GCS 15 without any risk-factors) or Mild head trauma (defined according to the HISS as a GCS score of 14 or 15 with risk factors (e.g. OAC-treatment, GCS = 14, repeated vomiting, loss of consciousness, age ≥ 65 and antiplatelet medication))
* No bleeding on initial head CT description
Exclusion Criteria:
* Other reasons for observation despite normal CT, based on the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults:
* GCS \< 14
* Post traumatic seizures
* Focal neurological deficits
* Clinical sign of depressed or basal skull fracture
* Shunt-treated hydrocephalus
Primary outcome measure(s)
Delayed Intracranial hemorrhage within 24 hours — 24 hours Hemorrhage found after initial CT scan but within 24 hours of trauma
Delayed Intracranial hemorrhage within 4 weeks — 4 weeks Hemorrhage found after initial CT scan but within 4 weeks of trauma
Thrombotic events — 1 week Arterial or venous thrombotic events experienced within one week of trauma
Deliria — During admission = up to 1 week after admission Description of deliria during admission for initial head trauma
Other injuries with a competing need for admission at another department — admission = up to 1 week after admission
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
